Dr. David Pisetsky curated the research presented at ACR Convergence 2025 and answers the question “What new research on psoriatic arthritis has the potential to impact patient care or future research?”
The ACR honors excellence in rheumatology. Meet the 2025 Awards of Distinction recipients, ACR Masters & Distinguished Fellows recognized at ACR Convergence 2025.
New research presented at ACR Convergence 2025 highlights how the Rheumatology Informatics System for Effectiveness (RISE) Registry—the nation’s largest collection of electronic health record data from rheumatology practices—is driving transformative improvements in quality, safety and outcomes in patients with rheumatic and musculoskeletal diseases. Research studies reveal that participation in and engagement with RISE not only…
Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.
In a session at EULAR 2025, Dr. Laura Coates discussed the management of PsA, providing insights into the current research and when clinicians may want to consider prescribing specific medications.
Supported by data in patients with new-onset and relapsing giant cell arteritis (GCA), the FDA approved upadacitinib for the treatment of adults with GCA.
‘Patients with rheumatologic diseases are rightfully concerned about the risk of flares after getting their COVID vaccines, especially after holding immune modulators,’ says says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘A new study is reassuring that flares are rare, even after holding or discontinuing immune modulators.’ The development of a vaccine for…